4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide

• ChemBase ID: 73114
• Molecular Formular: C22H19N5O
• Molecular Mass: 369.41916
• Monoisotopic Mass: 369.15896025
• SMILES: c1(cccc(n1)c1c(c2ccnc3c2cc(cc3)C(=O)N)c2n(n1)CCC2)C
• Canonical SMILES: Cc1cccc(n1)c1nn2c(c1c1ccnc3c1cc(cc3)C(=O)N)CCC2
• InChI: InChI=1S/C22H19N5O/c1-13-4-2-5-18(25-13)21-20(19-6-3-11-27(19)26-21)15-9-10-24-17-8-7-14(22(23)28)12-16(15)17/h2,4-5,7-10,12H,3,6,11H2,1H3,(H2,23,28)
• InChIKey: IVRXNBXKWIJUQB-UHFFFAOYSA-N

NAMES AND DATABASE IDS

Names

• IUPAC name: 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
• IUPAC Traditional name: 4-[2-(6-methylpyridin-2-yl)-4H,5H,6H-pyrrolo[1,2-b]pyrazol-3-yl]quinoline-6-carboxamide
• Synonyms: LY 2157299; LY2157299

Database IDs

• CAS Number: 700874-72-2
• PubChem SID: 162038034
• PubChem CID: 10090485

CALCULATED PROPERTIES

• Acid pKa: 14.581796
• H Acceptors: 4
• H Donor: 1
• LogD (pH = 5.5): 2.6348312
• LogD (pH = 7.4): 2.6377633
• Log P: 2.6378007
• Molar Refractivity: 117.8662 cm^3
• Polarizability: 44.08962 Å^3
• Polar Surface Area: 86.69 Å^2
• Rotatable Bonds: 2
• Lipinski's Rule of Five: true

PROPERTIES

Safety Information

• Storage Condition: -20°C

Pharmacology Properties

• Target: TGF-beta

Product Information

• Salt Data: Free Base

DETAILS

Selleck Chemicals - S2230

Research Area

• Description: Cancer

Biological Activity

• Description: LYLY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM.
• Targets: TβRI
• IC50: 56 nM ^[1]
• In Vitro: LY2157299 potently inhibits the TGFβ receptor signaling. LY2157299 abolishes the TGFβ induced Smad2 phosphorylation in HUVEC cells. LY2157299 also shows dose dependent potentiation of VEGF or bFGF induced cell proliferation in HUVEC. LY2157299 also promotes VEGF induced HUVEC cell migration. LY2157299 potentiates angiogenesis in the in vitro VEGF-stimulated cord formation assay. ^[2] LY2157299 inhibits TGF-β–mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells in a dose-dependent manner. LY2157199 treatment stimulates hematopoiesis from primary MDS bone marrow specimens. ^[3] In human glioblastoma (GBM) cells, LY2157299 treatment blocks signaling through the heteromeric TGFβ receptor complex to reduce levels of active, phosphorylated SMAD. ^[4]
• In Vivo: Although anti-tumor activity has been observed in several pre-clinical models, LY2157299 fails to show significant in vivo angiogenic effects in the 4T1, Colo205, or A549 xenograft models. ^[2] Administration of LY2157299 ameliorates anemia in a TGF-β overexpressing transgenic mouse model of bone marrow failure. ^[3] Oral administration of LY2157299 at 75 mg/kg/day displays significant antitumor activity against both Calu6 and MX1 xenografts in mice. ^[5] In vivo, LY2157299 induces angiogenesis and enhances VEGF and basic-fibroblast-growth-factor-induced angiogenesis in a Matrigel-plug assay, whereas adding an alpha5-integrin-neutralizing antibody to the Matrigel selectively inhibits this enhanced response. ^[6]
• Clinical Trials: A Phase II study of LY2157299 in patients with hepatocellular carcinoma is currently ongoing.

Protocol

• Protocol: Kinase Assay ^[1]
• TGF-β Type I (RIT204D) Receptors reaction: Reactions: 170-200 nM enzyme in 1 × KB (50 mM Tris pH 7.5, 150 mM NaCl, 4 mM MgCl₂, 1 mM NaF, 2 mM β-mercaptoethanol), LY2157299 dilution series in 1 × KB /16% DMSO (20 μM to 1 nM final concentration with 4% DMSO final concentration), reactions are started by adding ATP mix (4 μM ATP/ 1 μCi ^33P-α-ATP final concentrations) in 1 × KB. Reactions are incubated at 30 °C for 1 hour. Reactions are stopped and quantitated using standard TCA/BSA precipitation onto Millipore FB glass fiber filter plates and by liquid scintillation counting on a MicroBeta JET.
• Protocol: Animal Study ^[5]
• Animal Models: Nude mice implanted subcutaneously with Calu6 or MX1 cells
• Formulation: Dissolved in DMSO and diluted in saline
• Doses: 75 mg/kg/day
• Administration: Orally

References

• References: [1] Mundla SR, Patent, 2006, US7872020.
• References: [2] Yingling JM, et al. Proc Am Assoc Cancer Res. 2006, 47, abstract 250.
• References: [3] Zhou L, et al. Cancer Res, 2011, 71(3), 955-963.
• References: [4] Parsons S, et al. Mol Cancer Ther, 2011, 10(11), Suppl 1, Abst C201.
• References: [5] Bueno L, et al. Eur J Cancer, 2008, 44(1), 142-150.
• References: [6] Liu Z, et al. J Cell Sci, 2009, 122(18), 3294-3302.